Abstract
Cyclophosphamide in a dosage of 350 to 700 mg/m2/d was administered for five to 11 days to four patients with childhood adrenoleukodystrophy (ALD) and to one patient with the adult cerebral form of the disease. The rate of neurologic progression in the four patients with childhood ALD did not differ from that of 167 untreated patients with childhood ALD surveyed previously.
Publication types
-
Case Reports
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adrenoleukodystrophy / complications
-
Adrenoleukodystrophy / drug therapy*
-
Adult
-
Brain / diagnostic imaging
-
Brain / pathology
-
Child
-
Clinical Trials as Topic
-
Coma
-
Cyclophosphamide / therapeutic use*
-
Diffuse Cerebral Sclerosis of Schilder / drug therapy*
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Male
-
Nervous System Diseases / diagnostic imaging
-
Nervous System Diseases / drug therapy
-
Nervous System Diseases / etiology*
-
Radiography
-
Time Factors
Substances
-
Immunosuppressive Agents
-
Cyclophosphamide